This clinical intervention study evaluates a newly developed Brief SEE FAR CBT protocol for adults aged 18 years and older with posttraumatic stress disorder (PTSD), compared with dynamic psychotherapy treatment as usual. Participants in the Brief SEE FAR CBT group will receive 6 focused sessions emphasizing intrusive PTSD symptoms and will then continue to complete the full 12-session SEE FAR CBT protocol. Participants in the control group will receive dynamic psychotherapy as treatment as usual. Psychological outcomes will be assessed using self-report questionnaires at four time points: baseline, after 6 sessions, after 12 sessions, and at a 3-month follow-up. The study aims to examine changes in PTSD symptoms, anxiety, depression, perceived stress, resilience, somatic symptoms, sleep quality, and related psychological outcomes over the course of treatment and follow-up.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Brief SEE FAR CBT is a focused trauma-oriented cognitive-behavioral intervention based on the SEE FAR CBT approach. The brief protocol consists of 6 sessions delivered approximately once weekly, with emphasis on intrusive PTSD symptoms. Participants will then continue treatment to complete the full 12-session SEE FAR CBT protocol.
Participants will receive dynamic psychotherapy as treatment as usual, delivered approximately once weekly. This comparison condition represents the standard psychological treatment provided to participants in this clinical setting.
The Center for Psychological Services Sha'ar Hanegev
Sha'ar Hanegev, Israel
RECRUITINGChange in PTSD symptoms
PTSD Checklist for DSM-5 (PCL-5) PTSD symptoms will be assessed using the PCL-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be examined from baseline to after 6 sessions, from baseline to after 12 sessions, from baseline to 3-month follow-up, from after 6 sessions to after 12 sessions, and from after 12 sessions to 3-month follow-up.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in anxiety symptoms
Generalized Anxiety Disorder-7 (GAD-7) Anxiety symptoms will be assessed using the GAD-7. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be examined from baseline to after 6 sessions, from baseline to after 12 sessions, from baseline to 3-month follow-up, from after 6 sessions to after 12 sessions, and from after 12 sessions to 3-month follow-up.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in depressive symptoms
Patient Health Questionnaire-9 (PHQ-9) Depressive symptoms will be assessed using the PHQ-9. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Change in PHQ-9 total score will be examined across the four study assessment points.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in perceived stress
Perceived Stress Scale (PSS) Perceived stress will be assessed using the PSS. Total scores range from 0 to 40, with higher scores indicating greater perceived stress. Change in PSS total score will be examined across the four study assessment points.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in resilience
Connor-Davidson Resilience Scale (CD-RISC) esilience will be assessed using the CD-RISC. Total scores range from 0 to 40, with higher scores indicating greater resilience. Change in CD-RISC total score will be examined across the four study assessment points.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in somatic symptoms
Patient Health Questionnaire-15 (PHQ-15) Somatic symptoms will be assessed using the PHQ-15. Total scores range from 0 to 30, with higher scores indicating greater somatic symptom severity. Change in PHQ-15 total score will be examined across the four study assessment points.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in trauma-related use of imagination and coping
FRAME Trauma-related use of imagination and coping will be assessed using the FRAME questionnaire. The FRAME is a 21-item measure of fantastic reality ability, defined as the capacity to use imagination in response to stress or trauma. Items are rated on a 1-7 Likert scale, and mean scores range from 1 to 7, with higher scores indicating greater fantastic reality ability. Change in FRAME score will be examined across the four study assessment points.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in sleep quality
Brief Version of the Pittsburgh Sleep Quality Index Sleep quality will be assessed using the brief version of the Pittsburgh Sleep Quality Index. Change in sleep quality score will be examined across the four study assessment points.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in PTSD-related functional impairment
PTSD-related functional impairment will be assessed using the functional impairment section of the Posttraumatic Diagnostic Scale (PDS). This section includes 7 items assessing the extent to which PTSD-related problems interfered with work, relationships, leisure activities, family relationships, sex life, general life satisfaction, and overall functioning during the past two weeks. Items are rated from 0 to 4, and total scores range from 0 to 28, with higher scores indicating greater functional impairment. Change in functional impairment score will be examined across the four study assessment points.
Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.